Drug Trial Radar · NCT05609942
Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Sep 25, 2023
Primary completion
Jan 14, 2025
Study completion Mar 10, 2025
Sponsor
- Lead sponsor
- Blueprint Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Nov 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate elenestinib (BLU-263) in participants with Advanced Systemic Mastocytosis (AdvSM), SM with an associated hematologic neoplasm (SM-AHN), and other hematologic malignancies. The main questions it aims to answer are: * Determine Recommended Dose of elenestinib (BLU-263) monotherapy for participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) monotherapy * Efficacy of elenestinib (BLU-263) monotherapy in participants with AdvSM * Determine Recommended Dose of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM * Safety and tolerability of elenestinib (BLU-263) in combination with azacitidine * Efficacy of elenestinib (BLU-263) in combination with azacitidine in participants with AdvSM The estimated study duration for each participant will be approximately 4 years: 2 years of treatment followed by 2 years of follow-up. Participants may be required to attend monthly visits for the first six months, followed by quarterly visits for the remainder of the study.
Conditions
- Advanced Systemic Mastocytosis
Interventions
BLU-263Drug
BLU-263 Oral Tablets
AzacitidineDrug
Azacitidine powder for suspension for intravenous infusion / subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Number of Dose-limiting Toxicities (DLTs) (monotherapy only)Time frame: 28 Days
- Dose Escalation: Number of DLTs (combination therapy only)Time frame: 28 Days
- Dose Escalation and Expansion: Pure Pathological Response (PPR) Rate for SM in Selective KIT Inhibitor-naïve Participants (monotherapy only)Time frame: Up to approximately 4 years
- Dose Escalation and Expansion: Number of Participants with Adverse Events (AEs)Time frame: Up to approximately 4 years
- Dose Escalation and Expansion: Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to approximately 4 years
Locations
11 sites in 7 countries. Site status is shown where the registry gives one.
Stanford Cancer Institute
Palo Alto, California
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Huntsman Cancer Institute
Salt Lake City, Utah
Antwerp University Hospital
Edegem, Belgium
University Hospital Ghent
Ghent, Belgium
CHU Caen - Institut d'Hematologie de Basse Normandie
Caen, France
University Medical Centre Mannheim
Mannheim, Germany
Maastricht University Medical Center
Maastricht, Netherlands
Oslo University Hospital
Oslo, Norway
Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast)
Toledo, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.